Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesHematology/OncologySierra Health and Life Givosiran Coverage | OpenPa…
    Ask Trek AI about this page
    Currentsierra health and lifePolicy 2026D0087I

    Givosiran (Givlaari) — Coverage Criteria for Acute Hepatic Porphyria

    Customize your policy alerts

    Sign up for sierra health and life Policy 2026D0087I alerts

    Get alerted when Policy 2026D0087I changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Medical policy governing coverage criteria for givosiran (Givlaari) for treatment of adults with acute hepatic porphyria under specified benefit plans; applies to providers seeking authorization for therapy. Affects patients with diagnoses of AHP and clinicians/administrators requesting prior authorization.

    Policy Summary
    Payersierra health and life
    PolicyGivosiran (Givlaari) — Coverage Criteria for Acute Hepatic Porphyria
    Policy CodePolicy 2026D0087I
    Change TypeNo material changes
    Effective DateApr 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with documentation of AHP diagnosis and required attack history or current prophylactic hemin; initial auth limited to ≤12 months with dosing per FDA labeling.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2.5 mg/kgFDA recommended dosing
    70%ENVISION trial attack reduction

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ≤12 moInitial auth duration
    J0223HCPCS

    Coverage Criteria for Givosiran (Givlaari)

    Initial Therapy

    Covered when ALL of the following are met for Initial Therapy:

    Initial Therapy criteria: 1) Diagnosis of an acute hepatic porphyria (AHP) (acute intermittent porphyria, hereditary coproporphyria, variegate porphyria, or ALA dehydratase deficient porphyria);

    From Initial Therapy section

    Active disease or prophylaxis: 2) One of the following: a) Patient has active disease defined by at least 2 documented porphyria attacks within the past 6 months; OR b) Patient is currently receiving prophylactic hemin to prevent porphyria attacks;

    From Initial Therapy section

    Documentation: 3) Provider attestation that baseline hemin administration requirements and the rate and/or number of porphyria attacks have been documented;

    From Initial Therapy and Instructions for Use

    Transplant exclusion: 4) Patient has not had a liver transplant;

    Exclusion criterion

    Concomitant therapy exclusion: 5) Patient will not receive concomitant prophylactic hemin treatment while on Givlaari;

    Concurrent prophylactic hemin is not permitted

    Prescriber expertise: 6) Prescribed by, or in consultation with, a hematologist or specialist experienced in diagnosis and management of AHP;

    Specialist involvement required

    Dosing: 7) Givlaari dosing is in accordance with the United States FDA approved labeling;

    FDA labeling required (dose per label)

    Authorization duration: 8) Initial authorization will be for no more than 12 months;

    Authorization time limit

    Continuation Therapy

    Covered when ALL of the following are met for Continuation Therapy:

    Continuation Therapy criteria: 1) Patient has previously received Givlaari for the treatment of AHP;

    From Continuation Therapy section

    Clinical response: 2) Documentation that the patient has experienced a positive clinical response while on Givlaari;

    Response required for reauthorization

    Transplant exclusion: 3) Patient has not had a liver transplant;

    Exclusion criterion

    Concomitant therapy exclusion: 4) Patient will not receive concomitant prophylactic hemin treatment while on Givlaari;

    Concurrent prophylactic hemin is not permitted

    Coverage for givosiran (Givlaari) excludes patients who have had a liver transplant. The policy lists "Patient has not had a liver transplant" as a required criterion for both Initial Therapy and Continuation Therapy, and members who have undergone liver transplantation therefore do not meet the eligibility requirements for coverage.

    When assessing requests, reviewers should verify documentation of transplant history in the medical record (for example, operative reports, transplant clinic notes, or problem list entries). If a liver transplant is documented, the request should be denied because the patient does not satisfy the explicit exclusion in the coverage criteria.

    Concurrent use of prophylactic hemin is not permitted while a patient is receiving givosiran. The policy explicitly requires that the patient will not receive concomitant prophylactic hemin treatment while on Givlaari for both Initial Therapy and Continuation Therapy, and patients receiving prophylactic hemin at the time of request do not meet policy criteria.

    Providers must attest that baseline hemin administration (prophylactic or treatment) and attack history have been documented and that prophylactic hemin will be discontinued prior to initiating givosiran. Requests that indicate ongoing prophylactic hemin use should be denied or held until documentation shows hemin has been stopped in accordance with the policy requirement.

    Coding and Diagnosis References

    Covered HCPCS Codes (reference)HCPCS
    J0223Injection, givosiran, 0.5 mg
    Diagnosis Codes (reference)ICD-10
    E80.0Hereditary erythropoietic porphyria
    E80.1Porphyria cutanea tarda
    E80.20Unspecified porphyria
    E80.21Acute intermittent (hepatic) porphyria
    E80.29Other porphyria
    inv-07: Attack frequency — key clinical threshold
    Attack frequency thresholdAt least 2 documented porphyria attacks within the past 6 months (per ENVISION trial inclusion and Initial Therapy criterion)
    Attack definition for trial/policyAttacks requiring hospitalization, urgent healthcare visit, or intravenous hemin administration at home (ENVISION inclusion)
    Time window6‑month lookback period for documented attacks

    Provider Requirements and Authorization Actions

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for Givlaari (givosiran). Initial authorizations are limited to no more than 12 months and must document the diagnosis and criteria supporting medical necessity.

    • Initial authorization: up to 12 months
    • Prescribed by or in consultation with a hematologist or AHP specialist
    • Dosing per FDA labeling (2.5 mg/kg SC once monthly, based on actual body weight)
    Step Therapy

    Step Therapy / Sequencing

    Step therapy is not expressed as a required prior trial of a specific branded product, but coverage requires either a documented attack frequency or current prophylactic hemin use. Members must meet the stated clinical entry conditions before authorization will be approved.

    • Clinical entry: ≥2 documented porphyria attacks in the prior 6 months, OR current prophylactic hemin use

    Background on Acute Hepatic Porphyria and Givosiran

    Acute hepatic porphyria (AHP) refers to a family of ultra-rare genetic disorders caused by deficiencies in enzymes of hepatic heme biosynthesis. These conditions lead to accumulation of neurotoxic intermediates such as delta-aminolevulinic acid (ALA) and porphobilinogen (PBG), which are associated with recurrent neurovisceral attacks characterized by severe abdominal pain and neurologic and gastrointestinal symptoms.

    Givosiran (Givlaari) is an ALAS1-directed small interfering RNA that lowers hepatic ALAS1 mRNA, reducing ALA and PBG levels and thereby decreasing the frequency of porphyria attacks. The drug is indicated for adults with AHP meeting the coverage criteria described in this policy.

    Key Definitions

    inv-13: Definition of Acute Hepatic Porphyria (AHP)
    Disease familyAcute hepatic porphyria (AHP) is a family of ultra‑rare genetic diseases causing deficiency in hepatic heme biosynthesis enzymes
    Biochemical hallmarkElevated hepatic ALAS1 activity leads to increased circulating aminolevulinic acid (ALA) and porphobilinogen (PBG)
    Clinical manifestationsEpisodic neurovisceral attacks (severe unexplained abdominal pain, neurologic symptoms, nausea/vomiting, dark urine) and long‑term complications (hypertension, CKD, liver disease)
    inv-14: Definition of Givosiran (Givlaari)
    Drug class & mechanismGivosiran (Givlaari) is a double‑stranded small interfering RNA (siRNA) that degrades ALAS1 mRNA in hepatocytes via RNA interference
    Pharmacodynamic effect
    Policy Summary
    Payersierra health and life
    PolicyGivosiran (Givlaari) — Coverage Criteria for Acute Hepatic Porphyria
    Policy CodePolicy 2026D0087I
    Change TypeNo material changes
    Effective DateApr 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with documentation of AHP diagnosis and required attack history or current prophylactic hemin; initial auth limited to ≤12 months with dosing per FDA labeling.
    SourceLink
    On This Page
    Coverage Criteria for Givosiran (Givlaari)Coding and Diagnosis ReferencesProvider Requirements and Authorization ActionsBackground on Acute Hepatic Porphyria and GivosiranKey Definitions
    Prescriber expertise: 5) Prescribed by, or in consultation with, a hematologist or specialist experienced in diagnosis and management of AHP;

    Specialist involvement required

    Dosing: 6) Givlaari dosing is in accordance with the United States FDA approved labeling;

    FDA labeling required (dose per label)

    Authorization duration: 7) Reauthorization will be for no more than 12 months;

    Reauthorization time limit

  1. Note: Patients receiving prophylactic hemin may be considered under 'Initial Therapy' criteria but concurrent prophylactic hemin is not permitted while on Givlaari
  2. Documentation Required

    Required Documentation

    Providers must supply attestation and baseline documentation prior to initiation and at reauthorization to demonstrate treatment need and response.

    • Provider attestation documenting baseline hemin administration requirements (prophylactic or treatment) and baseline rate and/or number of porphyria attacks prior to initiating givosiran
    • Documentation of diagnosis consistent with AHP subtypes (e.g., acute intermittent porphyria, hereditary coproporphyria, variegate porphyria, ALA dehydratase deficient porphyria)
    • For continuation: documentation of prior Givlaari use and evidence of positive clinical response while on therapy
    • Prescriber specialty or consultation note (hematologist or AHP expert)
    Denial Risk

    Triggers for Denial

    Authorizations may be denied if required documentation or clinical criteria are not met.

    • Missing or insufficient documentation of AHP diagnosis
    • Failure to document the required baseline attack history (e.g., fewer than 2 attacks in the prior 6 months when required)
    • Documentation showing the member is receiving concurrent prophylactic hemin while requesting Givlaari
    • Evidence of prior liver transplant
    Reduces hepatic ALAS1 mRNA and lowers circulating neurotoxic intermediates ALA and PBG
    Clinical consequenceReduction in ALA/PBG levels is associated with decreased frequency of porphyria attacks (demonstrated in ENVISION trial)